Consolidation with VRD improves outcome in newly diagnosed MM
A second planned interim analysis of the EMN02/HOVON-95 trial confirms earlier promising results of consolidation treatment with VRD (bortezomib, lenalidomide, dexamethasone) followed by lenalidomide maintenance in newly diagnosed patients with multiple myeloma (NDMM), as was reported by Dr. Pieter Sonneveld (Erasmus MC, Rotterdam, The Netherlands).
In this study, NDMM patients were first randomized (R1) between intensification with VMP (bortezomib, melphalan, prednisone) vs HDM (high-dose melphalan) and autologous stem cell transplantation (ASCT). Next, patients were randomized a second time (R2) between consolidation with VRD vs no consolidation, followed by lenalidomide maintenance. VRD consolidation prolonged PFS from R2 with adjustment for R1 (HR 0.77; p=0.014), confirming the results of the first interim analysis, with a longer follow-up.